Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress and controversies in developing cancer vaccines.

Craig L Slingluff1, Daniel E Speiser

  • 1University of Virginia, Charlottesville, Virginia, USA. cls8h@virginia.edu.

Journal of Translational Medicine
|May 3, 2005
PubMed
Summary

Cancer vaccines show promise for immunotherapy, with progress in antigen identification and T cell response induction. Further research into cancer immunobiology and immune monitoring is crucial for developing effective, low-cost cancer treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterizing the Mutational Landscape of In-Transit Melanoma Metastases.

Pigment cell & melanoma research·2026
Same author

Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority-Serving Hospitals.

Cancer medicine·2026
Same author

Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab).

Cancer research communications·2026
Same author

Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

Journal for immunotherapy of cancer·2026
Same author

Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine Adjuvants.

Vaccines·2026

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Immunotherapy, utilizing cytokines and monoclonal antibodies, is a cornerstone of cancer management.
  • Cancer vaccines represent a promising immunotherapy approach, with advancements in identifying T cell-recognized antigens and inducing antigen-specific responses.

Discussion:

  • While some cancer vaccines have yielded dramatic tumor regressions, response rates remain low.
  • This article, part of a series on cancer vaccines and adoptive therapy, discusses the current status and challenges in cancer vaccination.
  • Improving understanding of cancer immunobiology and cellular immune monitoring post-vaccination is essential.

Key Insights:

  • Substantial progress has been made in identifying shared tumor antigens and developing vaccine strategies.

Related Experiment Videos

  • New technologies aid in monitoring immune responses within human tissues.
  • Dramatic clinical regressions have been observed, but low response rates necessitate further research.

    • Outlook:

    • Advancements in cancer immunobiology and immune monitoring will accelerate the development of effective cancer vaccines.
    • Effective cancer vaccines offer potential for low-cost, low-morbidity treatment and prevention.
    • Further development is needed to enhance the efficacy and broaden the application of cancer vaccines.